AFP、SF、β_2-MG联合检测在肝癌诊治中的价值  

Combined Detection of AFP,SF and β_2-MG in Diagnosis and Treatment of Liver Cancer

作　　者：朱金成[1] 牟焕梅[1] 沈超[1] 

机构地区：[1]山东中医药大学第二附属医院,山东济南250001

出　　处：《中国现代医生》2010年第19期21-22,共2页China Modern Doctor

摘　　要：目的探讨应用化学发光免疫分析法将多种肿瘤标志物联合检测对原发性肝癌的诊断价值。方法用化学发光法检测100例临床确诊的原发性肝癌(PHC)患者、80例肝硬化患者及200例健康体检者血清中AFP(甲胎蛋白)、SF(血清铁蛋白)及β2-MG(β2-微球蛋白)的水平。结果原发性肝癌三项指标与肝硬化及正常对照组相比较三项标志物,差异均有统计学意义(P<0.05)。原发性肝癌组单项AFP、SF、β2-MG阳性率分别为72%、67%、62%,三项联合检测阳性率为88%。结论 AFP、SF、β2-MG三项肿瘤标志物联合检测可提高肝癌的阳性符合率,对诊断及鉴别诊断肝癌具有实用价值。Objective To explore the diagnostic value of Joint detection of a variety of tumor markers by the CLIA method in primary liver cancer. Methods The chemiluminescence detection of serum AFP,SF and β2-MG levels was carried out in100 cases of confirmed primary liver cancer,80 cases of cirrhosis and 200 healthy volunteers. Results There were significant differences in the three indicators between primary liver cancer,cirrhosis and normal subjects（P〈0.05）. The positive rate of AFP,SF and β2-MG was72%,67% and 62%,respectively in primary liver cancer and the combined detection positive rate of the three indicators was 88%. Conclusion The combined detection of the three tumor markers AFP,SF and β2-MG can improve the positive consistent rate of liver cancer,with practical value in the diagnosis and differential diagnosis of liver cancer.

关 键 词：肿瘤标志物 原发性肝癌 AFP SF Β2-MG 

分 类 号：R735.7[医药卫生—肿瘤]